CG Oncology (CGON) Stock Forecast & Price Target

$33.47 +1.13 (+3.49%)

(As of 11/22/2024 ET)

CG Oncology - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 9 Analyst Ratings

Sell
0

Hold
0

Buy
9

Based on 9 Wall Street analysts who have issued ratings for CG Oncology in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 8 have given a buy rating, and 1 has given a strong buy rating for CGON.

Consensus Price Target

$63.88
90.84% Upside

According to the 9 analysts' twelve-month price targets for CG Oncology, the average price target is $63.88. The highest price target for CGON is $75.00, while the lowest price target for CGON is $50.00. The average price target represents a forecasted upside of 90.84% from the current price of $33.47.

Get the Latest News and Ratings for CGON and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CG Oncology and its competitors.

CGON Analyst Ratings Over Time

Type	Current Forecast 11/24/23 to 11/23/24	1 Month Ago 10/25/23 to 10/24/24	3 Months Ago 8/26/23 to 8/25/24	1 Year Ago 11/24/22 to 11/24/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	8 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$63.88	$63.88	$64.00	N/A
Forecasted Upside	90.84% Upside	75.24% Upside	72.88% Upside	N/A
Consensus Rating	Buy	Buy	Buy	N/A

JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

CGON Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CGON Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CG Oncology Stock vs. The Competition

Type	CG Oncology	Medical Companies	S&P 500
Consensus Rating Score	3.11	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	90.84% Upside	26,878.84% Upside	7.66% Upside
News Sentiment Rating	Positive News See Recent CGON News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/12/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00	+88.96%
10/24/2024	UBS Group 4 of 5 stars	D. Dai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00	+68.49%
10/8/2024	Bank of America 4 of 5 stars		Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00	+84.45%
9/23/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Renza Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$66.00	+69.23%
8/27/2024	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Paluch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/27/2024	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$65.00	+78.03%
5/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$43.00 ➝ $50.00	+93.50%
5/2/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Schimmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$75.00	+83.87%
2/20/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$55.00	+14.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:44 AM ET.

CGON Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for CG Oncology is $63.88, with a high forecast of $75.00 and a low forecast of $50.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CG Oncology in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CGON shares.
: According to analysts, CG Oncology's stock has a predicted upside of 90.84% based on their 12-month stock forecasts.
: Over the previous 90 days, CG Oncology's stock had 1 upgrade by analysts.
: CG Oncology has been rated by research analysts at Bank of America, HC Wainwright, Roth Capital, Roth Mkm, Royal Bank of Canada, and UBS Group in the past 90 days.
: Analysts like CG Oncology more than other "medical" companies. The consensus rating for CG Oncology is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CGON compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

This page (NASDAQ:CGON) was last updated on 11/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CG Oncology (CGON) Stock Forecast & Price Target